The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders. Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information. This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies. Download Full Report: http://bit.ly/2e3sl9Q

1. Best Practices, LLC Strategic Benchmarking Research
Medical Affairs’ Role in
Health Economics & Outcomes
Research within Oncology
1

2. Table of Contents
 Executive Summary pp. 3-9
 Research Objectives & Methodology pp. 3
 Participating Companies pp. 4
 Abbreviations pp. 5-6
 Key Findings & Insights pp. 7-9
 Longevity of HO Groups pp. 10-11
 HO Leadership pp. 12-13
 HO Reporting Structure pp. 14-15
 HO Group Staffing pp. 16-19
 MA’s Role in HO Activities pp. 20-23
 MA’s Role in Collecting HO Data pp. 24-25
 Utilization of HO Data pp. 26-32
 Impact of HO Data on Decisions pp. 33-36
 About Best Practices, LLC pp. 37-38
2

3. Field Research & Insight Development:
Ten survey responses from Medical Affairs leaders at top life-
science companies within mature markets
Analysis is focused on companies with oncology therapies
Additional deep-dive interviews with 5 selected Medical
Affairs executives- 2 VPs, 2 Directors and 1 Manager.
Provide Leading Insights on:
• Identify involvement level of
MA groups in HO activities
• Define opportunity fronts and
strategies to increase MA’s
role in HO data generation
and utilization
Research Objectives & Methodology
Research Objectives:
 Illustrate how Medical Affairs (MA) is involved in Health Outcomes (HO) data generation and utilization
 Highlight strategies for effective HO data communication and utilization
 Understand challenges about MA’s involvement in HO activities
 Identify industry drivers regarding HO groups
 Define resource levels for HO groups
Business Objective:
This research delivers current data, and best practices from Medical Affairs leaders with an oncology focus at top
biopharmaceutical companies. The data will help companies focused on oncology therapies find better ways to develop
successful Health Outcomes groups.
3

4. Universe of Learning: Research Participants from 2014-2015 Study
This study engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology
therapies.
Benchmark Class
4
Large Companies Segment

5. Segments and Abbreviations
5
Abbreviations:
• MA: Medical Affairs
• HO: Health Outcomes
• HEOR: Health Economics Outcomes Research
• TA: Therapeutic Areas
• TBC: Total Benchmark Class
• TL: Thought Leader
• TLM: Thought Leader Management

6. Key Findings & Insights: Medical Affairs’ Role in Health Outcomes Research
 Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of
the benchmark class; sixty percent of companies have had it in place for less than three years.
 Reporting Structure: Sixty percent of companies’ HO groups report to Medical Affairs. A majority of the
interviewed executives think that HO groups must report to a science and research oriented department
such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for
needs assessment, communicating HO data insights, and interacting with key decision makers.
 Medical Affairs’ Involvement in HO Activities: Medical Affairs is heavily involved in the clinical and
scientific research aspects of health outcomes activities. Over 70% of the Medical Affairs groups lead in
presenting pharma-economic data and developing clinical protocols for outcomes research.
6

7. Majority of Participants Have Had a HO Program for More Than Four Years
A majority of the participants have had a HO program in place for more than four years. However, 40% either don’t have a HO
program in place or their HO program is less than a year old.
N=10
Longevity of Health Outcomes Group(s): How long has the HO program been in place at your company?
% Respondents
7
No formal health
outcomes group, 10%
More than 5 years,
40%
4-5 years, 0%
1-3 years, 20%
Less than a year, 30%
Length of HO Program
+

8. A Quarter of Participants Don’t Use Traditional Reporting Structure
Sixty percent of the HO groups report to Medical Affairs within the benchmark class. Since HO is a recent trend, some
companies still haven’t clarified the reporting structure for these groups.
Reporting Structure: To whom does the Health Outcomes group(s) report?
% Respondents
8
N=10
Other: International Marketing and Medical Affairs
Other, 20%
Sales &
mrktg , 0%
Clinical
developme
nt, 20%
Medical
affairs,
60%
HO's Reporting Groups

9. Deliver
presentations/
speeches
Identify and
build
relationships
with outcomes-
focused KOLs
Gather relevant
customer
feedback &
report back to
appropriate
colleagues
Engage with
key medical,
outcomes and
commercial
colleagues
Present
pharmaco-
economic data
or HEOR
analysis
HO Groups Have Multi-Dimensional Field-Based Responsibilities
9
Core Field-Based HO Responsibilities
Field-Based HO
Responsibilities
Field-based health outcomes employees serve as a scientific bridge between companies and health care system decision
makers in managed care. The field-based team provides scientific, medical, and pharmaco-economic support to customers.
They also bring back feedback that can improve products.

10. MA Has a Weak Involvement in the Commercial Aspect of HO Activities
The most frequently lead activity by MA groups is presenting pharmaco-economic data, which is lead by 78%.
Training speakers on the outcomes data is the least often conducted activity within MA groups.
N= 8 - 9
Health Outcomes Activities: Please indicate the level of your Medical Affairs organization’s involvement
in each of the following activities.
% Respondents
10
78%
71%
56%
50%
44%
38%
38%
33%
13%
29%
44%
38%
56%
63%
25%
67%
75%
57%
11%
13%
14%
11%
38%
13%
29%
Presenting pharmaco-economic data
Developing clinical protocols for outcomes research
Delivering scientific presentations / speeches
Training commercial teams on outcomes data
Identifying payers and building relationships
Identifying providers and building relationshps
Training speakers on outcomes data
Formulary discussions with payers
Developing product labels
Developing commercial collaterals on outcomes
Medical Affair’s Involvement in HO Activities
Lead Support Plan to Participate in the Next 12 Months None

11. Burden of Illness is the HO Data that Resonates Across Stakeholders
Health
Outcomes
Data
Patients
ProvidersPayers
• Quality of Life
• Burden of Illness
• Analysis of Efficacy
• Analysis of Efficacy
• Analysis of Safety
• Burden of Illness
• Burden of Illness
• Cost Analysis
• Economic Analysis
DISEASE
MANAGEMENT
ECONOMIC
OUTCOMES &
COST REDUCTION
IMPACT ON
DAY-TO-DAY LIFE
Patients, Payers and Providers are interested in: Impact on daily life, Economic outcomes & Cost reduction, and Disease
management.
HO Data and Different Stakeholders

12. About Best Practices, LLC
12

13. Best Practices®, LLC is an internationally recognized thought leader in the field of best practice
benchmarking®. We are a research, consulting, benchmark database, publishing and advisory firm that
conducts work based on the simple yet profound principle that organizations can chart a course to superior
economic performance by leveraging the best business practices, operating tactics and winning strategies of
world-class companies.
6350 Quadrangle Drive, Suite 200
Chapel Hill, NC 27517
(Phone): 919-403-0251
www.best-in-class.com
Learn More About Our Company:
13